Although Novartis was the first company to win US Food and Drug Administration approval for a CAR-T cell therapy with Kymriah (tisagenlecleucel) back in 2017, the market has shifted in favor of competitors, particularly for diffuse large B-cell lymphoma (DLBCL). But the company is banking on data showing that its next-generation CAR-T agent rapcabtagene autoleucel can both improve response rates and offer greater convenience to patients thanks to its quick manufacturing time.
ASH: Novartis Looks To Challenge Frontline DLBCL Standard Of Care With Next-Gen CAR-T
The Swiss drug maker presented Phase II data at ASH for rapcabtagene autoleucel, also called YTB323, showing a 65% CR rate in relapsed/refractory diffuse large B-cell lymphoma.
